Potential Tumor Biomarkers for Ovarian Cancer

Serio, Ryan N; Billack, Blasé

doi:10.5772/28397

Cited by 2 publications

(2 citation statements)

References 231 publications

(244 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even though huge efforts have been undertaken to elucidate the biological nature of primary tumors and to identify new biomarkers in order to improve the treatment (Serio and Billack, 2011), many patients who were considered to be cured relapse even several years after resection/treatment of the primary tumor (Aktas et al, 2011;Martin and Schilder, 2009). It has already been shown that the presence of CTCs in ovarian cancer patients has predictive and prognostic relevance for the patient's OS and/or PFS (Abu-Rustum et al, 1999;Aktas et al, 2011;Kuhlmann et al, 2014;Poveda et al, 2011;Zeng et al, 2015;Zhou et al, 2015).…”

Section: Discussionmentioning

confidence: 99%

Gene expression profiling of single circulating tumor cells in ovarian cancer – Establishment of a multi‐marker gene panel

et al. 2016

View full text Add to dashboard Cite

The presence of circulating tumor cells (CTCs) in the blood of ovarian cancer patients was shown to correlate with decreased overall survival, whereby CTCs with epithelial–mesenchymal‐transition (EMT) or stem‐like traits are supposed to be involved in metastatic progression and recurrence. Thus, investigating the transcriptional profiles of CTCs might help to identify therapy resistant tumor cells and to overcome treatment failure. For this purpose, we established a multi‐marker panel for the molecular characterization of single CTCs, detecting epithelial (EpCAM, Muc‐1, CK5/7), EMT (N‐cadherin, Vimentin, Snai1/2, CD117, CD146, CD49f) and stem cell (CD44, ALDH1A1, Nanog, SOX2, Notch1/4, Oct4, Lin28) associated transcripts. First primer specificity and PCR‐performance of the multiplex‐RT‐PCRs were successfully validated on genomic DNA and cDNA isolated from OvCar3 cells. The assay sensitivity of the epithelial panel was evaluated by adding defined numbers of tumor cells into the blood of healthy donors and performing a subsequent immunomagnetic tumor cell enrichment (AdnaTest OvarianCancerSelect), resulting in a 100% concordance for the epithelial markers EpCAM and Muc‐1 to the AdnaTest OvarianCancerDetect. Additionally, by processing blood from ovarian cancer patients, high assay sensitivity could be verified. In blood of healthy donors no signals for epithelial markers were detected, for EMT and stem cell markers, however, signals were obtained mainly originating from leukocytes which calls for single cell analysis. To that aim by using the ovarian cancer cell line OvCar3, we successfully established a workflow enabling the characterization of single CTCs. It consists of a density gradient‐dependent enrichment for nucleated cells, a depletion of CD45‐positive cells of hematopoietic origin followed by immunofluorescent labeling of CTCs by EpCAM and Muc‐1. Single CTCs are then isolated by micromanipulation and processed for panel gene expression profiling. Finally, fifteen single CTCs from three ovarian cancer patients were analyzed and found to be positive for stem cell (CD44, ALDH1A1, Nanog, Oct4) and EMT markers (N‐cadherin, Vimentin, Snai2, CD117, CD146). Albeit, inter‐cellular and intra/inter‐patient heterogeneity and co‐expression of epithelial, mesenchymal and stem cell transcripts on the same CTC was observed. We have established a robust workflow to perform sensitive single cell panel gene expression analysis without the need of pre‐amplification steps. Our data point towards a heterogeneous expression of stem cell and EMT associated transcripts in ovarian cancer CTCs.

show abstract

Section: Discussionmentioning

confidence: 99%

Gene expression profiling of single circulating tumor cells in ovarian cancer – Establishment of a multi‐marker gene panel

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Due to their abundance and the importance of the roles they play in cellular functioning, carbohydrates can be useful biomarkers. 153 Despite this, progress in glycomics has been hindered by the available analytical methodology, as it is quite far behind that of proteomics and genomics. 154 This category includes simple monosaccharides and disaccharides such as glucose and fructose respectively, and more complex oligosaccharides and polysaccharides (Fig.…”

Section: Carbohydratesmentioning

confidence: 99%

Microfluidic platforms for biomarker analysis

et al. 2014

View full text Add to dashboard Cite

Biomarkers have been described as characteristics, most often molecular, that provide information about biological states, whether normal, pathological, or therapeutically modified. They hold great potential to assist diagnosis and prognosis, monitor disease, and assess therapeutic effectiveness. While a few biomarkers are routinely utilised clinically, these only reflect a very small percentage of all biomarkers discovered. Numerous factors contribute to the slow uptake of these new biomarkers, with challenges faced throughout the biomarker development pipeline. Microfluidics offers two important opportunities to the field of biomarkers: firstly, it can address some of these developmental obstacles, and secondly, it can provide the precise and complex platform required to bridge the gap between biomarker research and the biomarker-based analytical device market. Indeed, adoption of microfluidics has provided a new avenue for advancement, promoting clinical utilisation of both biomarkers and their analytical platforms. This review will discuss biomarkers and outline microfluidic platforms developed for biomarker analysis.

show abstract

Potential Tumor Biomarkers for Ovarian Cancer

Cited by 2 publications

References 231 publications

Gene expression profiling of single circulating tumor cells in ovarian cancer – Establishment of a multi‐marker gene panel

Gene expression profiling of single circulating tumor cells in ovarian cancer – Establishment of a multi‐marker gene panel

Microfluidic platforms for biomarker analysis

Contact Info

Product

Resources

About